Cite
Purcell JW, Kim HK, Tanlimco SG, et al. Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Front Immunol. 2014;4:505doi: 10.3389/fimmu.2013.00505.
Purcell, J. W., Kim, H. K., Tanlimco, S. G., Doan, M., Fox, M., Lambert, P., Chao, D. T., Sho, M., Wilson, K. E., Starling, G. C., & Culp, P. A. (2014). Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Frontiers in immunology, 4505. https://doi.org/10.3389/fimmu.2013.00505
Purcell, James W, et al. "Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR." Frontiers in immunology vol. 4 (2014): 505. doi: https://doi.org/10.3389/fimmu.2013.00505
Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, Chao DT, Sho M, Wilson KE, Starling GC, Culp PA. Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Front Immunol. 2014 Jan 08;4:505. doi: 10.3389/fimmu.2013.00505. eCollection 2014. PMID: 24409185; PMCID: PMC3884146.
Copy
Download .nbib